Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Status:
COMPLETED
Trial end date:
2024-06-21
Target enrollment:
Participant gender:
Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
Phase:
PHASE1
Details
Lead Sponsor:
Kallyope Inc.